BioVersys AG (FRA:W33) FFO


FRA:W33 BioVersys AG FRA:W33
7 GF Score
Price €28.00
View Full Analysis

What is BioVersys AG FFO?

FFO (Funds from operations) only applies to REITs.

FRA:W33
7GF Score
BioVersys AG FRA:W33
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioVersys AG Business Description

Other Exchanges BIOVz:UKBIOV:Switzerland
Address c/o Technologiepark, Hochbergerstrasse 60c, Basel, CHE, CH-4057
BioVersys AG is a multi-asset, clinical-stage biopharmaceutical company. The Group focuses on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The pipeline products of the company include BV100 - novel MoA, Alpibectir - novel potentiator MoA, BV200 - novel anti-virulence MoA, BV500 - novel series, and others. It has one operating segment focusing on the research and development and prospective commercialization of antibiotics. Geographically, the company operates in Switzerland and France.
7GF Score

Get the complete analysis for FRA:W33

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€28.00
Price